Abbreviations
Introduction
Medicine and the Hokkaido University Center for Environmental and Health Sciences.
159
This study was performed in accordance with principles of the Declaration of Helsinki.
160
Among the 514 participants, we excluded women who experienced miscarriage, 161 stillbirth, relocation, or voluntary withdrawal (n = 10), and women who delivered twins 162 (n = 7). 447 maternal blood samples were available for the PFOS and PFOA 
Exposure assessment

171
We used the data of PFOS and PFOA concentrations in maternal serum 172 measured by liquid chromatography-tandem mass spectrometry (LC/MS/MS) in our 173 previous study. Detailed methods for the measurement of PFOS and PFOA have been 174 described in our previous reports (Kishi et al., 2015; Nakata A, 2009 ). 6.9% of the 175 samples exhibited PFOA levels that were below the limit of detection (LOD; 0.50 ng/mL). In those cases, we assigned the sample a value of 0.25 ng/mL (50% of the 177 LOD).
178
Outcome measures
179
A blood sample (10-30 mL) was collected from the umbilical cord at the time 180 of delivery and was stored at -80°C until analysis. We analyzed cord blood samples for 181 their levels of E2, T, P4, LH, FSH, SHBG, prolactin (PRL), and inhibin B, as described 182 in our previous report (Araki et al., 2014) . The concentration of insulin-like factor 3 
Statistical analyses
200
The associations of PFOS and PFOA with the maternal and fetal characteristics 201 were explored using Spearman's correlation test and the Mann-Whitney U test.
202
Correlations of maternal serum PFOS and PFOA levels with cord blood reproductive 203 hormone levels were analyzed using Spearman's correlation test. We also performed 204 two different analyses: multiple linear regression analysis and dose-response analysis.
205
In the linear regression analysis, levels of PFOS, PFOA, and reproductive hormones 206 were converted using a log10 scale to account for their skewed distribution 207 (Supplemental Figure 1, 2) . In the dose-response analyses, PFOS and PFOA levels were 208 categorized into four quartiles, and reproductive hormones levels were converted using 209 a log10 scale. The least square means of each reproductive hormone were calculated 210 and back transformed. The p-value for trend was calculated using linear contrast 211 coefficient -3, -1, +1, +3 assigned to quartile first, second, third and fourth, respective (Goudarzi et al., 2016; Kishi et al., 2015 into the final models. All statistical analyses were performed using JMP Pro software
229
(version 12; SAS Institute Inc., NC, USA).
Results
232
Among the 189 mother-infant pairs, the median maternal levels of PFOS and 
243
The cord blood reproductive hormone levels are shown in levels. In the female infants, maternal PFOS was inversely correlated with PRL levels.
254
The relationships between maternal PFOS and PFOA levels and reproductive
255
hormone concentrations, according to our linear regression analyses for male and 256 female infants are shown in Table 4 and Table 5 , respectively. After fully adjusting for 
267
We also investigated the dose-response relationships between the quartiles of 268 maternal PFOS and PFOA levels and cord blood reproductive hormone levels (using 269 factors in Table 4 and 5 with a p-value of <0.1). Figure 1 
300
Median levels of PFOS and PFOA are 5.2 ng/mL and 1.4 ng/mL, respectively, which
301
were lower than in other areas of Japan (Harada et al., 2010) original cohort (n=514) (Supplemental Table 1 ). The level of PFOS among smoking 308 women was significantly lower than that of non-smoking women. Our result is 309 consistent with previous study.
310
There is few study that investigated the levels of reproductive hormone levels 311 in cord blood. Regarding the comparison of those levels in cord blood, our data in Table   312 2 did not differ dramatically from previous studies (Hollier et al., 2014; Kuijper et al., 313 2013; Warembourg et al., 2016) .
314
Among the male infants, we observed that maternal PFOS levels were 315 significantly and inversely associated with P4 levels and the T/E2 ratio, while 316 associated with increased E2 levels. We examined the T/E2 ratio as a marker of 317 aromatase activity, which convert T to E2 (Simpson et al., 1994 were delivered via vaginal birth. We compared the maternal and infant characteristics of 391 participants in this study with the original cohort population (n=514), as well as participants with PFOS and PFOA data before delivery (n=323) (Supplemental Table 1 ).
393
The infants in our analyses had a higher gestational age and a heavier birth weight. Table 4 and 5 as confounders, and the results were almost same as those in Table 4 and 430 were divided into 4 categories. PFOS: 1.5 ≦ Quartile (Q) 1 ≦ 3.9, 3.9 < Q2 ≦ 5. Adjusted for maternal factors (age, parity, body mass index before pregnancy, annual income, smoking during pregnancy, caffeine consumption during pregnancy, and gestational weeks of blood sampling for PFOS/PFOA measurement) and infant factors (gestational age at birth). PFOS: perfluorooctane sulfonate, PFOA: perfluorooctanoate, LH: luteinizing hormone, FSH: follicle stimulating hormone, SHBG: sex hormone-binding globulin, PRL: prolactin, INSL3: insulin-like 3. Adjusted for maternal factors (age, parity, body mass index before pregnancy, annual income, smoking during pregnancy, caffeine consumption during pregnancy, and gestational weeks of blood sampling for PFOS/PFOA measurement) and infant factors (gestational age at birth). PFOS: perfluorooctane sulfonate, PFOA: perfluorooctanoate, SHBG: sex hormone-binding globulin, PRL: prolactin
